Access the full text.
Sign up today, get DeepDyve free for 14 days.
Loading next page...
/lp/springer-journals/chronic-lymphocytic-leukemia-exploiting-vulnerabilities-with-targeted-j4M7d0LLBQ
References (95)
-
S. Tsukada, D. Saffran, D. Rawlings, O. Parolini, R. Allen, I. Klisak, R. Sparkes, H. Kubagawa, T. Mohandas, S. Quan, J. Belmont, M. Cooper, M. Conley, O. Witte (1993)
Deficient expression of a B cell cytoplasmic tyrosine kinase in human X-linked agammaglobulinemiaCell, 72
-
K. Kim, C. Crews (2013)
From epoxomicin to carfilzomib: chemistry, biology, and medical outcomes.Natural product reports, 30 5
-
M. Quiroga, K. Balakrishnan, A. Kurtova, M. Sivina, M. Keating, W. Wierda, V. Gandhi, J. Burger (2009)
B-cell antigen receptor signaling enhances chronic lymphocytic leukemia cell migration and survival: specific targeting with a novel spleen tyrosine kinase inhibitor, R406.Blood, 114 5
-
J. Woyach, R. Furman, Ta-Ming Liu, H. Ozer, M. Zapatka, A. Ruppert, L. Xue, Daniel Li, S. Steggerda, M. Versele, S. Dave, Jenny Zhang, A. Yilmaz, S. Jaglowski, K. Blum, A. Lozanski, G. Lozanski, D. James, J. Barrientos, P. Lichter, S. Stilgenbauer, J. Buggy, B. Chang, A. Johnson, J. Byrd (2014)
Resistance mechanisms for the Bruton's tyrosine kinase inhibitor ibrutinib.The New England journal of medicine, 370 24
-
J. Dubovsky, Kyle Beckwith, Gayathri Natarajan, J. Woyach, S. Jaglowski, Y. Zhong, J. Hessler, Ta-Ming Liu, B. Chang, K. Larkin, Matthew Stefanovski, D. Chappell, F. Frissora, Lisa Smith, Kelly Smucker, J. Flynn, Jeffrey Jones, L. Andritsos, K. Maddocks, A. Lehman, R. Furman, J. Sharman, A. Mishra, M. Caligiuri, A. Satoskar, J. Buggy, N. Muthusamy, A. Johnson, J. Byrd (2013)
Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes.Blood, 122 15
-
C. Rudin, C. Hann, E. Garon, Moacyr Oliveira, P. Bonomi, D. Camidge, Q. Chu, G. Giaccone, D. Khaira, S. Ramalingam, M. Ranson, C. Dive, E. Mckeegan, B. Chyla, B. Dowell, A. Chakravartty, C. Nolan, Nikita Rudersdorf, T. Busman, M. Mabry, A. Krivoshik, R. Humerickhouse, G. Shapiro, L. Gandhi (2012)
Phase II Study of Single-Agent Navitoclax (ABT-263) and Biomarker Correlates in Patients with Relapsed Small Cell Lung CancerClinical Cancer Research, 18
-
D. Hallaert, A. Jaspers, C. Noesel, M. Oers, A. Kater, E. Eldering (2008)
c-Abl kinase inhibitors overcome CD40-mediated drug resistance in CLL: implications for therapeutic targeting of chemoresistant niches.Blood, 112 13
-
Liguang Chen, J. Apgar, L. Huynh, F. Dicker, Teresa Giago-McGahan, L. Rassenti, A. Weiss, T. Kipps (2005)
ZAP-70 directly enhances IgM signaling in chronic lymphocytic leukemia.Blood, 105 5
-
J. Byrd, T. Lin, J. Dalton, Di Wu, M. Phelps, B. Fischer, M. Moran, K. Blum, B. Rovin, Michelle Brooker-McEldowney, Sarah Broering, L. Schaaf, A. Johnson, D. Lucas, N. Heerema, G. Lozanski, D. Young, J. Suárez, A. Colevas, M. Grever (2007)
Flavopiridol administered using a pharmacologically derived schedule is associated with marked clinical efficacy in refractory, genetically high-risk chronic lymphocytic leukemia.Blood, 109 2
-
M. Principe, G. Poeta, F. Buccisano, L. Maurillo, A. Venditti, A. Zucchetto, R. Marini, P. Niscola, M. Consalvo, C. Mazzone, L. Ottaviani, P. Panetta, A. Bruno, R. Bomben, G. Suppo, M. Degan, V. Gattei, P. Fabritiis, M. Cantonetti, F. Coco, D. Principe, S. Amadori (2006)
Clinical significance of ZAP-70 protein expression in B-cell chronic lymphocytic leukemia.Blood, 108 3
-
C. Tam, A. Grigg, Stephen Opat, M. Ku, M. Gilbertson, M. Anderson, J. Seymour, D. Ritchie, Carmen Dicorleto, Belinda Dimovski, E. Hedrick, Jianxin Yang, Lai Wang, L. Luo, L. Xue, A. Roberts (2015)
The BTK Inhibitor, Bgb-3111, Is Safe, Tolerable, and Highly Active in Patients with Relapsed/ Refractory B-Cell Malignancies: Initial Report of a Phase 1 First-in-Human TrialBlood, 126
-
(2013)
First-in-human study of AMG 319, a highly selective, small molecule inhibitor of PI3Kδ, in adult patients with relapsed or refractory lymphoid malignancies, in 55th ASH Annual meeting and exposition -
Russell Burke, S. Meadows, M. Loriaux, K. Currie, S. Mitchell, P. Maciejewski, A. Clarke, J. Dipaolo, B. Druker, B. Lannutti, S. Spurgeon (2014)
A potential therapeutic strategy for chronic lymphocytic leukemia by combining Idelalisib and GS-9973, a novel spleen tyrosine kinase (Syk) inhibitorOncotarget, 5
-
P. Thurmes, T. Call, S. Slager, C. Zent, G. Jenkins, S. Schwager, D. Bowen, N. Kay, T. Shanafelt (2008)
Comorbid conditions and survival in unselected, newly diagnosed patients with chronic lymphocytic leukemiaLeukemia & Lymphoma, 49
-
Shuai Dong, D. Guinn, J. Dubovsky, Y. Zhong, A. Lehman, J. Kutok, J. Woyach, J. Byrd, A. Johnson (2014)
IPI-145 antagonizes intrinsic and extrinsic survival signals in chronic lymphocytic leukemia cells.Blood, 124 24
-
M. Davids, J. Rodón, P. Abrisqueta, C. Egile, R. Ruiz-Soto, F. Awan (2013)
Update On The Safety and Efficacy Of The Pan Class I PI3K Inhibitor SAR245408 (XL147) In Chronic Lymphocytic Leukemia and Non-Hodgkin’s Lymphoma PatientsBlood, 122
-
F. Stevenson, S. Sahota, C. Ottensmeier, Delin Zhu, F. Forconi, T. Hamblin (2001)
The occurrence and significance of V gene mutations in B cell-derived human malignancy.Advances in cancer research, 83
-
S. Ponader, Shih-Shih Chen, J. Buggy, K. Balakrishnan, V. Gandhi, W. Wierda, M. Keating, S. O'brien, N. Chiorazzi, J. Burger (2012)
The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo.Blood, 119 5
-
(2015)
SEER cancer statistics factsheets: chronic lymphocytic leukemia, in SEER cancer statistics review, 1975–2012 -
A. Zelenetz, N. Lamanna, T. Kipps, S. Coutre, S. O'brien, Maria Aiello, Yoonjin Cho, R. Dubowy, I. Flinn (2014)
A Phase 2 Study of Idelalisib Monotherapy in Previously Untreated Patients ≥65 Years with Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)Blood, 124
-
Sofie Peirs, F. Matthijssens, S. Goossens, Inge Walle, K. Ruggero, C. Bock, S. Degryse, K. Canté-Barrett, D. Briot, E. Clappier, T. Lammens, B. Moerloose, Y. Benoît, B. Poppe, J. Meijerink, J. Cools, J. Soulier, T. Rabbitts, T. Taghon, F. Speleman, P. Vlierberghe (2014)
ABT-199 mediated inhibition of BCL-2 as a novel therapeutic strategy in T-cell acute lymphoblastic leukemia.Blood, 124 25
-
O. Hantschel, U. Rix, Uwe Schmidt, T. Bürckstümmer, M. Kneidinger, Gregor Schütze, J. Colinge, K. Bennett, W. Ellmeier, P. Valent, G. Superti-Furga (2007)
The Btk tyrosine kinase is a major target of the Bcr-Abl inhibitor dasatinibProceedings of the National Academy of Sciences, 104
-
L. Andritsos, Jeffrey Jones, A. Johnson, K. Maddocks, Elizabeth Wiley, K. Small, Eun Im, M. Grever, R. Bannerji, J. Byrd, Honghong Zhou (2013)
Dinaciclib (SCH 727965) Is a Novel Cyclin-Dependent Kinase (CDK) Inhibitor That Exhibits Activity In Patients With Relapsed Or Refractory Chronic Lymphocytic Leukemia (CLL)Blood, 122
-
Jennifer Brown, R. Furman, I. Flinn, S. Coutre, N. Wagner-Johnston, B. Kahl, S. Spurgeon, D. Benson, S. Peterman, D. Johnson, Daniel Li, R. Dansey, T. Jahn, J. Byrd (2013)
Final results of a phase I study of idelalisib (GSE1101) a selective inhibitor of PI3Kδ, in patients with relapsed or refractory CLL.Journal of Clinical Oncology, 31
-
J. Glassford, Inês Soeiro, Sara Skarell, L. Banerji, M. Holman, G. Klaus, T. Kadowaki, S. Koyasu, E. Lam (2003)
BCR targets cyclin D2 via Btk and the p85α subunit of PI3-K to induce cell cycle progression in primary mouse B cellsOncogene, 22
-
J. Byrd, Bonnie Harrington, S. O'brien, Jeffrey Jones, A. Schuh, S. Devereux, J. Chaves, W. Wierda, F. Awan, Jennifer Brown, P. Hillmen, D. Stephens, P. Ghia, J. Barrientos, J. Pagel, J. Woyach, D. Johnson, Jane Huang, Xiaolin Wang, A. Kaptein, B. Lannutti, T. Covey, M. Fardis, J. Mcgreivy, A. Hamdy, Wayne Rothbaum, R. Izumi, T. Diacovo, A. Johnson, R. Furman (2016)
Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia.The New England journal of medicine, 374 4
-
S. Cuni, P. Perez-Aciego, G. Perez-Chacon, Juan Vargas, Antonio Sánchez, F. Martín-Saavedra, Sara Ballester, J. García-Marco, Julia Jorda, A. Durántez (2004)
A sustained activation of PI3K/NF-κB pathway is critical for the survival of chronic lymphocytic leukemia B cellsLeukemia, 18
-
P. Amrein, E. Attar, T. Takvorian, E. Hochberg, K. Ballen, K. Leahy, D. Fisher, A. LaCasce, E. Jacobsen, P. Armand, R. Hasserjian, L. Werner, D. Neuberg, Jennifer Brown (2011)
Phase II Study of Dasatinib in Relapsed or Refractory Chronic Lymphocytic LeukemiaClinical Cancer Research, 17
-
M. Gold, R. Ingham, Sarah McLeod, S. Christian, M. Scheid, V. Duronio, L. Santos, L. Matsuuchi (2000)
Targets of B‐cell antigen receptor signaling: the phosphatidylinositol 3‐kinase/Akt/glycogen synthase kinase‐3 signaling pathway and the Rap1 GTPaseImmunological Reviews, 176
-
J. Bubien, L Zhou, P. Bell, R. Frizzell, T. Tedder (1993)
Transfection of the CD20 cell surface molecule into ectopic cell types generates a Ca2+ conductance found constitutively in B lymphocytesThe Journal of Cell Biology, 121
-
J. Byrd, R. Furman, S. Coutre, I. Flinn, J. Burger, K. Blum, B. Grant, J. Sharman, M. Coleman, W. Wierda, Jeffrey Jones, Weiqiang Zhao, N. Heerema, A. Johnson, J. Sukbuntherng, B. Chang, F. Clow, E. Hedrick, J. Buggy, D. James, S. O'brien (2013)
Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia.The New England journal of medicine, 369 1
-
(2013)
Preliminary safety and efficacy of IPI-145, a potent inhibitor of phosphoinositide-3-kinase-delta, gamma, in patients with chronic lymphocytic leukemia, in ASH annual meeting and exposition -
J. Sharman, M. Hawkins, K. Kolibaba, M. Boxer, L. Klein, Meihua Wu, Jing Hu, S. Abella, C. Yasenchak (2015)
An open-label phase 2 trial of entospletinib (GS-9973), a selective spleen tyrosine kinase inhibitor, in chronic lymphocytic leukemia.Blood, 125 15
-
Sneha Gupta, E. Hertlein, Yanhui Lu, E. Sass, R. Lapalombella, Timothy Chen, Melanie Davis, J. Woyach, A. Lehman, D. Jarjoura, J. Byrd, D. Lucas (2013)
The Proteasome Inhibitor Carfilzomib Functions Independently of p53 to Induce Cytotoxicity and an Atypical NF-κB Response in Chronic Lymphocytic Leukemia CellsClinical Cancer Research, 19
-
M. Suljagić, P. Longo, S. Bennardo, E. Perlas, G. Leone, L. Laurenti, D. Efremov (2010)
The Syk inhibitor fostamatinib disodium (R788) inhibits tumor growth in the Eμ- TCL1 transgenic mouse model of CLL by blocking antigen-dependent B-cell receptor signaling.Blood, 116 23
-
W. Khan, F. Alt, R. Gerstein, B. Malynn, I. Larsson, G. Rathbun, L. Davidson, Sussane Müller, A. Kantor, Leonora Herzenberg, F. Rosen, P. Sideras (1995)
Defective B cell development and function in Btk-deficient mice.Immunity, 3 3
-
Yin-Hua Wang, L. Fan, Li Wang, Run Zhang, Zhi-jian Zou, Cheng Fang, Li-Na Zhang, Jian-yong Li, W. Xu (2013)
Expression levels of Lyn, Syk, PLCγ2 and ERK in patients with chronic lymphocytic leukemia, and higher levels of Lyn are associated with a shorter treatment-free survivalLeukemia & Lymphoma, 54
-
A. Delmer, F. Ajchenbaum‐Cymbalista, R. Tang, S. Ramond, A. Faussat, J. Marie, R. Zittoun (2000)
Overexpression of Cyclin D 2 in Chronic B-Cell Malignancies -
J. Friedberg, J. Sharman, J. Sweetenham, P. Johnston, J. Vose, A. LaCasce, Julia Schaefer-Cutillo, S. Vos, R. Sinha, J. Leonard, L. Cripe, S. Gregory, Michael Sterba, A. Lowe, R. Levy, M. Shipp (2010)
Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia.Blood, 115 13
-
Zhijian Chen (2005)
Ubiquitin signalling in the NF-κB pathwayNature Cell Biology, 7
-
S. Herman, Amber Gordon, E. Hertlein, A. Ramanunni, Xiaoli Zhang, S. Jaglowski, J. Flynn, Jeffrey Jones, K. Blum, J. Buggy, A. Hamdy, A. Johnson, J. Byrd (2011)
Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765.Blood, 117 23
-
C. Campás, Ana Cosialls, M. Barragán, Daniel Iglesias-Serret, Antonio Santidrián, Llorenç Coll‐Mulet, M. Frías, A. Domingo, G. Pons, J. Gil (2006)
Bcl-2 inhibitors induce apoptosis in chronic lymphocytic leukemia cells.Experimental hematology, 34 12
-
Ingrid Marschitz, Inge Tinhofer, Anton Hittmair, A. Egle, M. Kos, R. Greil (2000)
Analysis of Bcl-2 protein expression in chronic lymphocytic leukemia. A comparison of three semiquantitation techniques.American journal of clinical pathology, 113 2
-
I. Flinn, J. Byrd, N. Bartlett, T. Kipps, J. Gribben, D. Thomas, R. Larson, K. Rai, R. Petric, Jose Ramon-Suerez, J. Gabrilove, M. Grever (2005)
Flavopiridol administered as a 24-hour continuous infusion in chronic lymphocytic leukemia lacks clinical activity.Leukemia research, 29 11
-
A. Johnson, Yuh-Ying Yeh, Lisa Smith, Amy Wagner, J. Hessler, Sneha Gupta, J. Flynn, Jeffrey Jones, Xiaoli Zhang, R. Bannerji, M. Grever, J. Byrd (2012)
The novel cyclin-dependent kinase inhibitor dinaciclib (SCH727965) promotes apoptosis and abrogates microenvironmental cytokine protection in chronic lymphocytic leukemia cellsLeukemia, 26
-
S. O'brien, Jeffrey Jones, S. Coutre, A. Mato, P. Hillmen, C. Tam, A. Österborg, T. Siddiqi, M. Thirman, R. Furman, O. Ilhan, M. Keating, T. Call, Jennifer Brown, M. Stevens-Brogan, Yunfeng Li, M. Fardis, F. Clow, D. James, A. Chu, M. Hallek, S. Stilgenbauer (2014)
Efficacy and Safety of Ibrutinib in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Leukemia with 17p Deletion: Results from the Phase II RESONATE™-17 TrialBlood, 124
-
S. Gobessi, L. Laurenti, P. Longo, S. Sica, G. Leone, D. Efremov (2007)
ZAP-70 enhances B-cell-receptor signaling despite absent or inefficient tyrosine kinase activation in chronic lymphocytic leukemia and lymphoma B cells.Blood, 109 5
-
D. Stephens, Kyle Beckwith, C. Cheney, X. Mo, J. Flynn, Jeffrey Jones, K. Maddocks, K. Heider, N. Muthusamy, J. Byrd (2014)
BI 836826, a Novel Fc-Engineered Antibody in Combination with Phosphoinositide-3-Kinase Inhibitor for Treatment of High Risk Chronic Lymphocytic LeukemiaBlood, 124
-
S. Lanham, T. Hamblin, D. Oscier, R. Ibbotson, F. Stevenson, G. Packham (2003)
Differential signaling via surface IgM is associated with VH gene mutational status and CD38 expression in chronic lymphocytic leukemia.Blood, 101 3
-
B. Lamothe, F. Cervantes-Gomez, M. Sivina, W. Wierda, M. Keating, V. Gandhi (2015)
Proteasome inhibitor carfilzomib complements ibrutinib's action in chronic lymphocytic leukemia.Blood, 125 2
-
Zhijian Chen (2005)
Ubiquitin signalling in the NF-kappaB pathway.Nature cell biology, 7 8
-
KM Kortuem, AK Stewart (2013)
CarfilzomibBlood, 121
-
S. Herman, P. Barr, Erin McAuley, Delong Liu, A. Wiestner, J. Friedberg (2013)
Fostamatinib inhibits B-cell receptor signaling, cellular activation and tumor proliferation in patients with relapsed and refractory chronic lymphocytic leukemiaLeukemia, 27
-
Rong Chen, M. Keating, V. Gandhi, W. Plunkett (2005)
Transcription inhibition by flavopiridol: mechanism of chronic lymphocytic leukemia cell death.Blood, 106 7
-
V. Chan, Ingrid Mecklenbräuker, I. Su, G. Texidó, M. Leitges, R. Carsetti, C. Lowell, K. Rajewsky, K. Miyake, A. Tarakhovsky (1998)
The Molecular Mechanism of B Cell Activation by toll-like Receptor Protein RP-105The Journal of Experimental Medicine, 188
-
D. Rossi, S. Rasi, V. Spina, Marco Fangazio, S. Monti, M. Greco, Carmela Ciardullo, Rosella Famà, S. Cresta, A. Bruscaggin, L. Laurenti, M. Martini, P. Musto, F. Forconi, R. Marasca, L. Larocca, R. Foà, G. Gaidano (2012)
Different impact of NOTCH1 and SF3B1 mutations on the risk of chronic lymphocytic leukemia transformation to Richter syndromeBritish Journal of Haematology, 158
-
Veronica Balatti, A. Bottoni, Alexey Palamarchuk, H. Alder, L. Rassenti, T. Kipps, Y. Pekarsky, C. Croce (2012)
NOTCH1 mutations in CLL associated with trisomy 12.Blood, 119 2
-
Liguang Chen, G. Widhopf, L. Huynh, L. Rassenti, K. Rai, A. Weiss, T. Kipps (2002)
Expression of ZAP-70 is associated with increased B-cell receptor signaling in chronic lymphocytic leukemia.Blood, 100 13
-
R. Furman, Zahra Asgary, J. Mascarenhas, H. Liou, E. Schattner (2000)
Modulation of NF-kappa B activity and apoptosis in chronic lymphocytic leukemia B cells.Journal of immunology, 164 4
-
J. Byrd, B. Peterson, J. Gabrilove, O. Odenike, M. Grever, K. Rai, R. Larson (2005)
Treatment of Relapsed Chronic Lymphocytic Leukemia by 72-Hour Continuous Infusion or 1-Hour Bolus Infusion of Flavopiridol: Results from Cancer and Leukemia Group B Study 19805Clinical Cancer Research, 11
-
J. Somoza, David Koditek, Armando Villase, Nor, N. Novikov, Melanie Wong, Albert, Liclican, Weimei Xing, Leanna Lagpacan, Ruth Wang, B. Schultz, Giuseppe Papalia, D. Samuel, L. Lad, M. Mcgrath (2015)
Structural, biochemical and biophysical characterization of idelalisib binding to phosphoinositide 3-kinase delta* -
L. Honigberg, Ashley Smith, M. Sirisawad, E. Verner, D. Loury, B. Chang, Shyr-Jiann Li, Z. Pan, D. Thamm, Richard Miller, J. Buggy (2010)
The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancyProceedings of the National Academy of Sciences, 107
-
Victoria Moore, Jennifer Brown, Michael Certo, Tara Love, C. Novina, A. Letai (2007)
Chronic lymphocytic leukemia requires BCL2 to sequester prodeath BIM, explaining sensitivity to BCL2 antagonist ABT-737.The Journal of clinical investigation, 117 1
-
A. Souers, J. Leverson, E. Boghaert, S. Ackler, Nathaniel Catron, Jun Chen, B. Dayton, H. Ding, S. Enschede, W. Fairbrother, D. Huang, S. Hymowitz, Sha Jin, S. Khaw, P. Kovar, L. Lam, Jackie Lee, H. Maecker, K. Marsh, K. Mason, M. Mitten, Paul Nimmer, Anatol Oleksijew, Chang Park, Cheol-min Park, D. Phillips, A. Roberts, D. Sampath, J. Seymour, Morey Smith, G. Sullivan, S. Tahir, Chris Tse, M. Wendt, Yu Xiao, John Xue, Haichao Zhang, R. Humerickhouse, S. Rosenberg, S. Elmore (2013)
ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing plateletsNature Medicine, 19
-
F. Awan, J. Flynn, Jeffrey Jones, L. Andritsos, K. Maddocks, E. Sass, M. Lucas, Weihong Chase, Sharon Waymer, Yonghua Ling, Yao Jiang, M. Phelps, J. Byrd, D. Lucas, J. Woyach (2015)
Phase I dose escalation trial of the novel proteasome inhibitor carfilzomib in patients with relapsed chronic lymphocytic leukemia and small lymphocytic lymphomaLeukemia & Lymphoma, 56
-
J. Byrd, Jennifer Brown, S. O'brien, J. Barrientos, N. Kay, N. Reddy, S. Coutre, C. Tam, S. Mulligan, U. Jaeger, S. Devereux, P. Barr, R. Furman, T. Kipps, F. Cymbalista, C. Pocock, P. Thornton, F. Caligaris‐cappio, T. Robak, J. Delgado, S. Schuster, M. Montillo, A. Schuh, S. Vos, D. Gill, A. Bloor, C. Dearden, C. Moreno, Jeffrey Jones, A. Chu, M. Fardis, J. Mcgreivy, F. Clow, D. James, P. Hillmen (2014)
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.The New England journal of medicine, 371 3
-
J. Petro, S. Rahman, D. Ballard, W. Khan (2000)
Bruton's Tyrosine Kinase Is Required for Activation of Iκb Kinase and Nuclear Factor κb in Response to B Cell Receptor EngagementThe Journal of Experimental Medicine, 191
-
E. Rosati, R. Sabatini, Giuliana Rampino, A. Tabilio, M. Ianni, K. Fettucciari, A. Bartoli, S. Coaccioli, I. Screpanti, P. Marconi (2009)
Constitutively activated Notch signaling is involved in survival and apoptosis resistance of B-CLL cells.Blood, 113 4
-
S. Hewamana, S. Alghazal, T. Lin, Matthew Clement, C. Jenkins, M. Guzman, C. Jordan, Sundar Neelakantan, P. Crooks, A. Burnett, G. Pratt, C. Fegan, C. Rowntree, P. Brennan, C. Pepper (2008)
The NF-kappaB subunit Rel A is associated with in vitro survival and clinical disease progression in chronic lymphocytic leukemia and represents a promising therapeutic target.Blood, 111 9
-
S. Kabak, B. Skaggs, M. Gold, M. Affolter, Kelly West, Mark Foster, K. Siemasko, A. Chan, R. Aebersold, M. Clark (2002)
The Direct Recruitment of BLNK to Immunoglobulin α Couples the B-Cell Antigen Receptor to Distal Signaling PathwaysMolecular and Cellular Biology, 22
-
D. Parry, T. Guzi, F. Shanahan, Nicole Davis, Deepa Prabhavalkar, Derek Wiswell, W. Seghezzi, K. Paruch, M. Dwyer, R. Doll, A. Nomeir, W. Windsor, T. Fischmann, Yaolin Wang, M. Oft, Taiying Chen, P. Kirschmeier, E. Lees (2010)
Dinaciclib (SCH 727965), a Novel and Potent Cyclin-Dependent Kinase InhibitorMolecular Cancer Therapeutics, 9
-
C. Noesel, G. Brouns, G. Schijndel, R. Bende, D. Mason, J. Borst, R. Lier (1992)
Comparison of human B cell antigen receptor complexes: membrane- expressed forms of immunoglobulin (Ig)M, IgD, and IgG are associated with structurally related heterodimersThe Journal of Experimental Medicine, 175
-
J. Burger, M. Keating, W. Wierda, Julia Hoellenriegel, Ghayathri Jeyakumar, A. Ferrajoli, S. Faderl, M. Cárdenas-Turanzas, S. Lerner, Gracy Zacharian, Xuelin Huang, H. Kantarjian, S. O'brien (2013)
Ibrutinib In Combination With Rituximab (iR) Is Well Tolerated and Induces a High Rate Of Durable Remissions In Patients With High-Risk Chronic Lymphocytic Leukemia (CLL): New, Updated Results Of a Phase II Trial In 40 PatientsBlood, 122
-
M. Vega, S. Huerta-Yepez, Melisa Martínez-Paniagua, B. Martínez-Miguel, R. Hernández-Pando, C. González-Bonilla, P. Chinn, N. Hanna, K. Hariharan, Ali Jazirehi, B. Bonavida (2009)
Rituximab-Mediated Cell Signaling and Chemo/Immuno-sensitization of Drug-Resistant B-NHL Is Independent of Its Fc FunctionsClinical Cancer Research, 15
-
J. Woyach, A. Johnson, J. Byrd (2012)
The B-cell receptor signaling pathway as a therapeutic target in CLL.Blood, 120 6
-
Z. Pan, H. Scheerens, Shyr-Jiann Li, B. Schultz, P. Sprengeler, Leland Burrill, Rohan Mendonca, Michael D. Sweeney, Keana C. K. Scott, P. Grothaus, D. Jeffery, J. Spoerke, L. Honigberg, P. Young, S. Dalrymple, J. Palmer (2007)
Discovery of Selective Irreversible Inhibitors for Bruton’s Tyrosine KinaseChemMedChem, 2
-
I. Giudice, D. Rossi, S. Chiaretti, M. Marinelli, Simona Tavolaro, S. Gabrielli, L. Laurenti, R. Marasca, S. Rasi, Marco Fangazio, A. Guarini, G. Gaidano, R. Foà (2012)
NOTCH1 mutations in +12 chronic lymphocytic leukemia (CLL) confer an unfavorable prognosis, induce a distinctive transcriptional profiling and refine the intermediate prognosis of +12 CLLHaematologica, 97
-
K. Paruch, M. Dwyer, C. Alvarez, Courtney Brown, T. Chan, R. Doll, Kerry Keertikar, Chad Knutson, B. Mckittrick, Jocelyn Rivera, R. Rossman, Greg Tucker, T. Fischmann, A. Hruza, V. Madison, A. Nomeir, Yaolin Wang, P. Kirschmeier, E. Lees, D. Parry, Nicole Sgambellone, W. Seghezzi, L. Schultz, F. Shanahan, Derek Wiswell, Xiaoying Xu, Quiao Zhou, R. James, V. Paradkar, Haengsoon Park, Laura Rokosz, Tara Stauffer, T. Guzi (2010)
Discovery of Dinaciclib (SCH 727965): A Potent and Selective Inhibitor of Cyclin-Dependent Kinases.ACS medicinal chemistry letters, 1 5
-
T. Lin, A. Ruppert, A. Johnson, B. Fischer, N. Heerema, L. Andritsos, K. Blum, J. Flynn, Jeffrey Jones, Weihong Hu, M. Moran, S. Mitchell, Lisa Smith, Amy Wagner, C. Raymond, L. Schaaf, M. Phelps, M. Villalona-Calero, M. Grever, J. Byrd (2009)
Phase II study of flavopiridol in relapsed chronic lymphocytic leukemia demonstrating high response rates in genetically high-risk disease.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 27 35
-
M. MacConmara, J. Lederer (2005)
B cells.Critical care medicine, 33 12 Suppl
-
A. Souers, J. Leverson, E. Boghaert, S. Ackler, C. Nathaniel, Jun Chen, B. Dayton, Ding Hong, S. Enschede, W. Fairbrother, D. Huang, S. Hymowitz, Sha Jin, S. Khaw, P. Kovar, L. Lam, Jackie Lee, H. Maecker, K. Marsh, K. Mason, M. Mitten, Paul Nimmer, Anatol Oleksijew, H. ParkChang, Cheol‐Min Park, D. Phillips, A. Roberts, D. Sampath, J. Seymour, Morey Smith, M. SullivanGerard, S. Tahir, Chris Tse, M. Wendt, Yu Xiao, John Xue, Haichao Zhang, R. Humerickhouse, S. Rosenberg, W. ElmoreSteven (2013)
Souers AJ, Leverson JD, Boghaert ER et al.ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat Med 19:202-208 -
Laura Rozan, W. El-Deiry (2007)
p53 downstream target genes and tumor suppression: a classical view in evolutionCell Death and Differentiation, 14
-
M. Santos, L. Sarmento, M. Rebelo, Ana Doce, I. Maillard, Alexis Dumortier, Hélia Neves, F. Radtke, W. Pear, L. Parreira, J. Demengeot (2007)
Notch1 engagement by Delta-like-1 promotes differentiation of B lymphocytes to antibody-secreting cellsProceedings of the National Academy of Sciences, 104
-
J. Somoza, David Koditek, A. Villaseñor, N. Novikov, Melanie Wong, Albert Liclican, Weimei Xing, Leanna Lagpacan, Ruth Wang, B. Schultz, Giuseppe Papalia, D. Samuel, L. Lad, M. Mcgrath (2015)
Structural, Biochemical, and Biophysical Characterization of Idelalisib Binding to Phosphoinositide 3-Kinase δ*The Journal of Biological Chemistry, 290
-
X. Puente, M. Pinyol, V. Quesada, L. Conde, G. Ordóñez, N. Villamor, G. Escaramís, P. Jares, S. Beà, M. González-Díaz, L. Bassaganyas, T. Baumann, M. Juan, M. López-Guerra, D. Colomer, J. Tubío, C. López, A. Navarro, C. Tornador, M. Aymerich, M. Rozman, J. Hernández, Diana Puente, J. Freije, G. Velasco, A. Gutiérrez-Fernández, D. Costa, Anna Carrió, S. Guijarro, A. Enjuanes, L. Hernández, J. Yagüe, Pilar Nicolàs, C. Romeo-Casabona, H. Himmelbauer, Ester Castillo, J. Dohm, S. Sanjosé, M. Piris, E. Álava, J. Miguel, R. Royo, J. Gelpí, D. Torrents, M. Orozco, D. Pisano, A. Valencia, R. Guigó, M. Bayés, S. Heath, M. Gut, P. Klatt, J. Marshall, K. Raine, L. Stebbings, P. Futreal, Michael Stratton, Peter Campbell, I. Gut, A. López-Guillermo, X. Estivill, E. Montserrat, C. López-Otín, E. Campo (2011)
Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemiaNature, 475
-
S. Pierce (2002)
Lipid rafts and B-cell activationNature Reviews Immunology, 2
-
A. Delmer, F. Ajchenbaum‐Cymbalista, R. Tang, S. Ramond, A. Faussat, Marie Jp, R. Zittoun (1995)
Overexpression of cyclin D2 in chronic B-cell malignancies.Blood, 85 10
-
J. Blachly, R. Baiocchi (2014)
Targeting PI3‐kinase (PI3K), AKT and mTOR axis in lymphomaBritish Journal of Haematology, 167
-
R. Furman, J. Sharman, S. Coutre, B. Cheson, J. Pagel, P. Hillmen, J. Barrientos, A. Zelenetz, T. Kipps, I. Flinn, P. Ghia, H. Eradat, T. Ervin, N. Lamanna, B. Coiffier, A. Pettitt, Shuo Ma, S. Stilgenbauer, P. Cramer, Maria Aiello, D. Johnson, L. Miller, Daniel Li, T. Jahn, R. Dansey, M. Hallek, S. O'brien (2014)
Idelalisib and rituximab in relapsed chronic lymphocytic leukemia.The New England journal of medicine, 370 11
-
R. Furman, Zahra Asgary, J. Mascarenhas, H. Liou, E. Schattner (2000)
Modulation of NF-κB Activity and Apoptosis in Chronic Lymphocytic Leukemia B Cells1The Journal of Immunology, 164
-
Shuo Ma, D. Brander, J. Seymour, T. Kipps, J. Barrientos, M. Davids, M. Anderson, M. Anderson, M. Choi, C. Tam, Tanita Mason-Bright, B. Prine, W. Munasinghe, Ming Zhu, S. Kim, R. Humerickhouse, A. Roberts, A. Roberts (2015)
Deep and Durable Responses Following Venetoclax (ABT-199 / GDC-0199) Combined with Rituximab in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia: Results from a Phase 1b StudyBlood, 126
-
R. Lapalombella, Yuh-Ying Yeh, Liwen Wang, A. Ramanunni, S. Rafiq, S. Jha, Justin Staubli, D. Lucas, R. Mani, S. Herman, A. Johnson, A. Lozanski, L. Andritsos, Jeffrey Jones, J. Flynn, B. Lannutti, P. Thompson, P. Algate, S. Stromatt, D. Jarjoura, X. Mo, Dasheng Wang, Ching Chen, G. Lozanski, N. Heerema, S. Tridandapani, Michael Freitas, N. Muthusamy, J. Byrd (2012)
Tetraspanin CD37 directly mediates transduction of survival and apoptotic signals.Cancer cell, 21 5
-
Josephine Klitgaard, Reuma Magori-Cohen, R. Improgo, S. Fernandes, B. Tesar, Kevin Hoang, Haesook Kim, Jennifer Brown (2014)
Inhibition of the Notch1 Pathway in Chronic Lymphocytic Leukemia Promotes Apoptosis and Inhibits ProliferationBlood, 124
-
R. Dielschneider, W. Xiao, J-Y Yoon, E. Noh, V. Banerji, Hongzhao Li, A. Marshall, J. Johnston, S. Gibson (2014)
Gefitinib targets ZAP-70-expressing chronic lymphocytic leukemia cells and inhibits B-cell receptor signalingCell Death & Disease, 5
-
S. Braselmann, V. Taylor, Haoran Zhao, Suizhao Wang, C. Sylvain, M. Baluom, K. Qu, E. Herlaar, Angela Lau, C. Young, B. Wong, S. Lovell, T. Sun, G. Park, A. Argade, S. Jurcevic, P. Pine, Rajinder Singh, E. Grossbard, D. Payan, E. Masuda (2006)
R406, an Orally Available Spleen Tyrosine Kinase Inhibitor Blocks Fc Receptor Signaling and Reduces Immune Complex-Mediated InflammationJournal of Pharmacology and Experimental Therapeutics, 319
- Publisher
- Springer Journals
- Copyright
- Copyright © 2016 by Springer Science+Business Media New York
- Subject
- Medicine & Public Health; Hematology; Oncology; Geriatrics/Gerontology
- ISSN
- 1558-8211
- eISSN
- 1558-822X
- DOI
- 10.1007/s11899-016-0299-0
- pmid
- 26893063
- Publisher site
- See Article on Publisher Site
Abstract
The field of oncology has been transformed over the course of the last 20 years in large part due to the enhanced understanding of cellular biology and cellular signaling. The indolent natural history of chronic lymphocytic leukemia (CLL) has permitted extensive study of cancer biology and can in some ways be thought of a model for understanding and translating concepts to other diseases. By systematically probing the biology of CLL cells and working out in stepwise fashion the transduction of signals from the surface immunoglobulin to nuclear transcription factors, investigators have paved the way for rational targeting of therapies at natural vulnerabilities that mimic oncogene addiction. These key targets include Bruton’s tyrosine kinase (BTK), phosphatidylinositol 3-kinase (PI3K), Src, Bcl2, and cyclin-dependent kinases (CDKs). In this review, we will consider these proteins and describe the current and future molecules designed to target them in CLL.
Journal
Current Hematologic Malignancy Reports – Springer Journals
Published: Feb 11, 2016